Baselake Partners, LP Reports New 5.2% Stake in TherapeuticsMD, Inc. (TXMD)

On April 6, 2026, Baselake Partners, LP, Baselake Management, LLC, and David Paolella filed a Schedule 13G regarding their holdings in TherapeuticsMD, Inc. (TXMD). The filing reports a new ownership position of 607,181 shares of Common Stock, representing 5.2% of the company based on 11,574,362 shares outstanding as of March 30, 2026. This position reflects an increase from a previously reported 0.0% ownership stake. The shares are held directly by Baselake Partners, LP. Baselake Management, LLC serves as the investment manager, and David Paolella acts as the managing member of the investment manager. Consequently, all three reporting persons are deemed to share voting and dispositive power over the reported shares. The filing was made pursuant to Rule 13d-1(c), certifying that the securities were not acquired for the purpose of changing or influencing the control of the issuer. The principal business office for the reporting persons is located in Troy, Michigan.